Holen Sie sich die Stockscreener-App
12.28
0.57%
0.07
Schlusskurs vom Vortag:
$12.21
Offen:
$12.3
24-Stunden-Volumen:
402.31K
Relative Volume:
0.38
Marktkapitalisierung:
$644.26M
Einnahmen:
$1.02B
Nettoeinkommen (Verlust:
$-757.20M
KGV:
-0.832
EPS:
-14.76
Netto-Cashflow:
$-257.90M
1W Leistung:
+4.78%
1M Leistung:
+21.34%
6M Leistung:
+94.61%
1J Leistung:
+50.49%
1-Tages-Spanne:
$12.20
$12.71
1-Wochen-Bereich:
$11.34
$12.71
52-Wochen-Spanne:
$4.02
$13.41
Emergent Biosolutions Inc Stock (EBS) Company Profile
Firmenname
Emergent Biosolutions Inc
Sektor
Telefon
240-631-3200
Adresse
300 PROFESSIONAL DR, GAITHERSBURG, MD
Vergleichen Sie EBS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
12.27 | 641.27M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
123.46 | 53.87B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.87 | 45.71B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.885 | 43.73B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.09 | 34.49B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
508.29 | 22.00B | 3.08B | 1.24B | 1.07B | 25.61 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-03-07 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-08-29 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Eingeleitet | The Benchmark Company | Buy |
| 2021-02-24 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-07-31 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-09-04 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Hochstufung | Goldman | Neutral → Buy |
| 2018-08-03 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-06-13 | Eingeleitet | Argus | Buy |
| 2018-04-25 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2018-01-16 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | Singular Research | Buy |
| 2016-04-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-03-28 | Eingeleitet | Singular Research | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2014-05-15 | Eingeleitet | Summer Street Research | Buy |
| 2011-05-31 | Bestätigt | WBB Securities | Strong Buy |
| 2011-01-10 | Bestätigt | Wedbush | Outperform |
| 2010-11-05 | Bestätigt | Wedbush | Outperform |
| 2010-08-18 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Bestätigt | Caris & Company | Buy |
Alle ansehen
Emergent Biosolutions Inc Aktie (EBS) Neueste Nachrichten
VP Lowry Surrenders 3,543 Of Emergent BioSolutions Inc [EBS] - TradingView — Track All Markets
Emergent BioSolutions (EBS) insider has shares withheld to cover taxes - Stock Titan
Emergent Biosolutions (NYSE:EBS) Earns Buy Rating from HC Wainwright - MarketBeat
EBS: HC Wainwright & Co. Reiterates Buy Rating and $15 Price Tar - GuruFocus
HC Wainwright & Co. Reiterates Emergent BioSolutions (EBS) Buy Recommendation - Nasdaq
Emergent Biosolutions (NYSE:EBS) Trading 5.9% HigherHere's Why - MarketBeat
Emergent BioSolutions Earnings Notes - Trefis
Energy Moves: Can Emergent BioSolutions Inc stock weather global recessionEarnings Growth Summary & Trade Opportunity Analysis Reports - moha.gov.vn
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site - The Manila Times
Emergent BioSolutions (NYSE: EBS) gains FDA OK for Winnipeg raxibacumab drug product site - Stock Titan
Emergent BioSolutions (NYSE: EBS) gains FDA approval for raxibacumab production - Stock Titan
Emergent BioSolutions Inc Stock Analysis and ForecastEvening Star Patterns & Low Risk Capital Growth Plans - earlytimes.in
Emergent Biosolutions (NYSE:EBS) Director Sells $263,148.48 in Stock - MarketBeat
Emergent BioSolutions (EBS) director reports option exercise and stock sales - Stock Titan
Emergent Biosolutions Q1 2025 Earnings Preview - MSN
EBS (NYSE: EBS) holder files Form 144 to sell 32,848 shares - Stock Titan
What makes Emergent BioSolutions Inc. stock appealing to growth investorsTrade Risk Report & AI Driven Stock Reports - Newser
Emergent Biosolutions Inc. $EBS Stock Holdings Increased by Geode Capital Management LLC - MarketBeat
How cyclical is Emergent BioSolutions Inc. (ER4) stock compared to rivalsMarket Risk Report & Free Reliable Trade Execution Plans - Newser
Will Emergent BioSolutions Inc. stock split again soonBull Run & Daily Risk Controlled Trade Plans - Newser
Will Emergent BioSolutions Inc. stock reach Wall Street targets2025 Big Picture & Advanced Swing Trade Entry Plans - Newser
How Emergent BioSolutions Inc. (ER4) stock behaves in tightening cyclesTrade Entry Summary & Daily Growth Stock Investment Tips - Newser
Will Emergent BioSolutions Inc. (ER4) stock extend growth storyJuly 2025 EndofMonth & Reliable Price Action Trade Plans - Newser
Published on: 2025-12-04 04:37:47 - Newser
Is Emergent BioSolutions Inc. (ER4) stock protected from inflationJuly 2025 Drop Watch & Low Drawdown Investment Strategies - Newser
Will Emergent BioSolutions Inc. (ER4) stock top growth indexesM&A Rumor & AI Driven Price Forecasts - Newser
EBS SEC FilingsEmergent Biosolutions Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Published on: 2025-12-03 01:19:03 - Newser
How Emergent BioSolutions Inc. stock compares to market leadersJuly 2025 Opening Moves & Technical Buy Zone Confirmations - Newser
Why ETFs are accumulating Emergent BioSolutions Inc. stockInsider Selling & Free Verified High Yield Trade Plans - Newser
Why Emergent BioSolutions Inc. stock is popular among millennialsInflation Watch & Weekly Top Stock Performers List - Newser
Why Emergent BioSolutions Inc. (ER4) stock remains top ratedDip Buying & Advanced Swing Trade Entry Alerts - Newser
Emergent BioSolutions (EBS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
What technical patterns form on Emergent BioSolutions Inc. (ER4) stock chartsPortfolio Value Report & Risk Controlled Swing Alerts - Newser
Why Emergent BioSolutions Inc. stock trades below fair value2025 Volatility Report & Weekly Chart Analysis and Guides - Newser
Will Emergent BioSolutions Inc. stock justify high valuationWatch List & Daily Market Momentum Tracking - Newser
Emergent Biosolutions (NYSE:EBS) Upgraded at Wall Street Zen - MarketBeat
Emergent Biosolutions Inc. diskutieren - sharewise.com
EBS (Emergent BioSolutions) Debt-to-EBITDA : 1.72 (As of Sep. 2025) - GuruFocus
Stock Report: Why Emergent BioSolutions Inc. stock is a must watch tickerEarnings Overview Report & Long-Term Investment Growth Plans - BỘ NỘI VỤ
Emergent BioSolutions up 10% on HC Wainwright buy initiation - MSN
Should Emergent BioSolutions Inc. (NYSE:EBS) Focus On Improving This Fundamental Metric? - 富途牛牛
Performance Recap: How risky is Emergent BioSolutions Inc. stock nowPortfolio Value Summary & Free Accurate Trade Setup Notifications - BỘ NỘI VỤ
Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt - simplywall.st
Emergent Biosolutions (NYSE:EBS) Trading 10.4% HigherHere's Why - MarketBeat
With Emergent BioSolutions Stock Surging, Have You Considered The Downside? - Trefis
Emergent Biosolutions marks 10 years since FDA approval of NARCAN with Emmitt Smith - Traders Union
Why Emergent BioSolutions Inc. stock could outperform in 2025Weekly Profit Report & Advanced Swing Trade Entry Alerts - newser.com
Is Emergent BioSolutions Inc. stock undervalued at current price2025 Historical Comparison & AI Enhanced Trading Signals - newser.com
Is Emergent BioSolutions Inc. stock undervalued historicallyJuly 2025 News Drivers & Consistent Growth Stock Picks - newser.com
Why Emergent BioSolutions Inc. (ER4) stock is trending on social media2025 Institutional Moves & High Yield Stock Recommendations - newser.com
Finanzdaten der Emergent Biosolutions Inc-Aktie (EBS)
Umsatz
Nettogewinn
Free Cashflow
ENV
10.41%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):